Hypoactive sexual desire disorder, or HSDD, is the most common female sexual dysfunction with about 10% of premenopausal women in the US believed to have this condition. HSDD is consistently under diagnosed, and under managed due to the lack of adequate physician-patient communication on this topic.
In this article, Dr. Mache Seibel will discuss the symptoms of HSDD, and its impact on a patient’s quality of life along with the components for a comprehensive sexual history. Also discussed will be the tools for screening and diagnosing HSDD, as well as therapeutic modalities available and processes of the FDA-mandated Risk Evaluation and Mitigation Strategy (REMS) Program.
After participating in this educational activity, participants should be better able to:
Identify the symptoms of hypoactive sexual desire disorder
Cite barriers in their clinical practice that inhibit the appropriate diagnosis and management of HSDD
Describe the components of a comprehensive sexual history
Identify the screening tools that allow for accurate diagnosis of HSDD
Explain causal factors for HSDD and common co-morbid conditions
Identify the therapeutic modalities available to manage HSDD including their benefits and potential side effects – also including the first agent approved for this indication (flibanserin)
Identify the processes of the FDA-mandated Risk Evaluation and Mitigation Strategy (REMS) Program that will allow healthcare providers/pharmacies to prescribe/dispense flibanserin